InsiderPulse
← 10-K / 10-Q
10-QCPMD

CANNAPHARMARX, INC.

Filed 2026-05-20Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
Revenue$627K+87.1%
Cost of Revenue$1.0M+23.7%
Gross Profit-$409K+18.5%
SG&A Expense$36K+29.2%
Operating Income-$682K-2.2%
Interest Expense$476K-22.7%
Net Income-$382K+44.7%
EPS (Diluted)$0.00

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$633-47.6%-47.6%
Accounts Receivable$7K-95.8%
Inventory$903K-19.0%-5.1%
Current Assets$930K-29.1%-24.8%
Total Assets$6.6M-6.2%-41.4%
Current Liabilities$31.5M-0.3%+17.1%
Total Liabilities$36.9M-0.9%+16.1%
Stockholders' Equity-$30.3M-0.4%-47.6%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$244K+59.5%
Financing Cash Flow$242K-59.6%